Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

5

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

5 results for “loco-regional treatment”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov32/100

Assessing Impact of Loco-regional Treatment on Survival in Metastatic Breast Cancer at Presentation

ClinicalTrials.gov study NCT00193778. IPD Sharing: Not stated. Countries: 1. Publications: 9.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer

ClinicalTrials.gov study NCT04276857. IPD Sharing: UNDECIDED. Countries: 1. Publications: 14.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov20/100

Efficacy of Loco-regional Treatment for Hepatocellular Carcinoma Prior to Living Donor Liver Transplantation in Egypt

ClinicalTrials.gov study NCT02990351. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
zenodo16/100

Dataset related to article "High prevalence of multidrug-resistant bacteria in patients with pyogenic liver abscess following liver cancer loco-regional treatments"

<p>This record contains raw data related to article &ldquo;High prevalence of multidrug-resistant bacteria in patients with pyogenic liver abscess following liver cancer loco-regional treatments&quot;</p> <p>Liver abscess is a rare condition, associated with significant in-hospital mortality. Because of improved diagnostic yield and standardized treatment strategies, mortality has been reduced from 70% to 6% in the last decades.<sup><a href="https://onlinelibrary.wiley.com/doi/10.1111/liv.14933#liv14933-bib-0001">1</a>, <a href="https://onlinelibrary.wiley.com/doi/10.1111/liv.14933#liv14933-bib-0002">2</a></sup></p> <p>The aetiology of pyogenic liver abscess (PLA) varies according to geographical areas and is relevant to tailor treatment strategies; in Western countries, 80% of PLA are bacterial with <em>Escherichia coli</em>, other Enterobacteriaceae and anaerobes being the most common microorganisms. In Asia, <em>Klebsiella</em> <em>pneumoniae</em> has emerged as the most common pathogen in the last two decades, with up to 81.1% of cases reported in Taiwan.<sup><a href="https://onlinelibrary.wiley.com/doi/10.1111/liv.14933#liv14933-bib-0003">3</a>, <a href="https://onlinelibrary.wiley.com/doi/10.1111/liv.14933#liv14933-bib-0004">4</a></sup> Interestingly, increasing frequencies of PLA from <em>K</em>. <em>pneumonia</em> have also been observed in Europe and the United States.<sup><a href="https://onlinelibrary.wiley.com/doi/10.1111/liv.14933#liv14933-bib-0005">5</a></sup></p> <p>The most common risk factors for PLA include primary liver tumour and metastases, loco-regional liver procedures and liver cysts.</p> <p>The treatment of PLA with antibiotic therapy, percutaneous drainage and management of the underlying cause is the current standard of care; however, the recommended antibiotic regimen and the optimal duration of treatment remain uncertain.</p> <p>Yin et al<sup><a href="https://onlinelibrary.wiley.com/doi/10.1111/liv.14933#liv14933-bib-0006">6</a></sup> reported in a retrospective study the management of 1572 patients with PLA in China. The most identified microorganism was <em>K. pneumoniae</em> (85.6%), with an overall mortality of 4.5% following abscess drainage and antibiotic therapy. Prognosis was associated with length of hospitalization, fever, pleural effusion and development of multiple organ dysfunction.</p> <p>Given the increase in incidence of multi-drug resistant (MDR) infections in the western world and the differences in aetiology of PLA between geographical areas, we analysed the aetiology and mortality of PLA in our centre, focusing on the prevalence and factors associated with MDR bacterial infections</p> <p>&nbsp;</p>

restrictedJan 2022View details →
zenodo16/100

Dataset related to article "Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy "

<p>This record contains raw data related to article &ldquo;Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy&quot;</p> <p><strong>Background: </strong> Loco-regional therapy (LRT) in de novo metastatic breast cancer (MBC) has been investigated in several clinical trials, with heterogeneous and conflicting results.</p> <p><strong>Methods: </strong> We conducted a retrospective study of de novo MBC patients treated with front-line chemotherapy (FLC) followed by LRT of the primary tumor. Our aims were to evaluate the characteristics, treatment, and oncological outcomes in terms of progression-free survival (PFS), distant progression-free survival (DPFS), and overall survival (OS) of de novo MBC. We also investigated possible subgroups of patients with better outcomes according to menopausal status, biological sub-type, location, number of metastases, and radiologic complete response after FLC.</p> <p><strong>Results: </strong> We included 61 patients in the study. After a median follow-up of 55 months, disease progression occurred in 60.7% of patients and 49.2% died. There were no significant differences in PFS, DPFS, and OS between different subgroups of de novo MBC patients. A trend toward better PFS and DPFS was observed in triple-positive tumors, without a statistically significant difference in OS.</p> <p><strong>Conclusions: </strong> No specific subgroup of de novo MBC patients showed a statistically significant survival advantage after FLC followed by LRT of the primary tumor.</p> <p>&nbsp;</p>

restrictedJan 2023View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record